<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942054</url>
  </required_header>
  <id_info>
    <org_study_id>SCO-120-19-22</org_study_id>
    <nct_id>NCT04942054</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve&#xD;
      advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and&#xD;
      prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and&#xD;
      PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC&#xD;
      patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or&#xD;
      with out ESR1 mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 &amp; 2: Approximately 51 subjects will be enrolled Part 3: Approximately 90 subjects will&#xD;
      be enrolled&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a 3 X 3 Design, sequential doses of 300 mg, 600 mg, 800 mg, 1200 mg will be studied. Other dose strength will be studied based on results.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities at each dose levels (Part 1 only)</measure>
    <time_frame>28 Days/End of Cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events with each dose level</measure>
    <time_frame>upto 30 days of last dose</time_frame>
    <description>The intensity of adverse events will be graded as per CTCAE, Version 5.0 and categorized as serious adverse events or non-serious adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of Cmax (Part 1 and Part 2)</measure>
    <time_frame>Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)</time_frame>
    <description>Pharmacokinetic analysis will be performed using non-compartmental analysis. The actual elapsed time from dose will be used in the final pharmacokinetic parameter calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of tmax (Part 1 and Part 2)</measure>
    <time_frame>Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)</time_frame>
    <description>Pharmacokinetic analysis will be performed using non-compartmental analysis. The actual elapsed time from dose will be used in the final pharmacokinetic parameter calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of AUC (Part 1 and Part 2)</measure>
    <time_frame>Through Cycle 1 and Cycle 2 (Each cycle of 28 Days)</time_frame>
    <description>Pharmacokinetic analysis will be performed using non-compartmental analysis. The actual elapsed time from dose will be used in the final pharmacokinetic parameter calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumour response</measure>
    <time_frame>Every 8 weeks, for 'Time point Response (Partial Response[PR], Stable Disease[SD], Disease progression [DP] or Complete Response [CR]), Through study completion, an average of 1 year.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>pharmacodynamic biomarker</measure>
    <time_frame>At Screening and End of Cycle 1' (Each Cycle of 28 days)</time_frame>
    <description>Pharmacodynamic Biomarkers [Estrogen receptor (ER) expression, Ki67 down regulation from Tissue Biopsy, and Estrogen receptor occupancy with [(18)F] Fluoroestradiol Positron Emission Tomography (18F-FES PET) scan]</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Hormone Receptor-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SCO-120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1</intervention_name>
    <description>Dose escalation cohort</description>
    <arm_group_label>SCO-120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2</intervention_name>
    <description>Pharmacodyanamic (PD) dose exploration cohorts</description>
    <arm_group_label>SCO-120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 3</intervention_name>
    <description>Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort</description>
    <arm_group_label>SCO-120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All 3 parts of Study:&#xD;
&#xD;
               -  Male or females, Age 18 years or older&#xD;
&#xD;
               -  Histologically or cytologically diagnosed with ER+/HER2- adenocarcinoma of the&#xD;
                  breast cancer with an evidence of metastatic/loco-regionally recurrent&#xD;
                  disease/unresectable advanced disease not amenable to treatment with curative&#xD;
                  intent&#xD;
&#xD;
               -  Documentation of ER-positive, HER2-negative status determined based on a biopsy&#xD;
                  performed at or after diagnosis of local or metastatic recurrence, utilizing an&#xD;
                  assay consistent with local standards&#xD;
&#xD;
               -  Not more than 3 prior chemotherapeutic regimens&#xD;
&#xD;
               -  ECOG performance status 0-1.&#xD;
&#xD;
               -  Resolution of all adverse events of prior therapy or surgical procedures to&#xD;
                  National Cancer Institute (NCI) CTCAE v 5.0 Grade ≤1 (except alopecia)&#xD;
&#xD;
               -  Adequate organ and immune system function as indicated by laboratory values&#xD;
&#xD;
               -  Patients of childbearing potential must practice an acceptable method of birth&#xD;
                  control as judged by the Investigator&#xD;
&#xD;
               -  Female subjects must be non-lactating and non-breast feeding&#xD;
&#xD;
               -  Male subjects should not father a child and must practice an acceptable method of&#xD;
                  birth control measures Willing and available to participate for the entire study&#xD;
&#xD;
               -  Willing and able to comply with protocol requirements&#xD;
&#xD;
          2. For Part 1&amp; 2:&#xD;
&#xD;
               -  Patient must have evaluable disease (according to RECIST 1.1).&#xD;
&#xD;
               -  Documented disease progression or resistance to at least 1 prior endocrine&#xD;
                  therapy (with or without CDK 4/6 therapy).&#xD;
&#xD;
          3. For Part 3&#xD;
&#xD;
               -  Patient must have measurable lesions (according to RECIST 1.1)&#xD;
&#xD;
               -  Part 3a: HR+ve, HER2- MBC patients with ESR1 mutations, resistance to atleast one&#xD;
                  priro endocrine therapy&#xD;
&#xD;
               -  Part 3b: HR+ve HER2- MBC patients resistant to atleast one priro endocrine&#xD;
                  therapy&#xD;
&#xD;
               -  Part 3c: HR+ve HER2- MBC patients resistant to atleast one priro endocrine&#xD;
                  therapy, disease progression on Fulvestrant and CDK4/6i&#xD;
&#xD;
               -  Part 3d: Brain metastases secondary to ER+ve HER-ve Breast Cancer:&#xD;
&#xD;
        Measurable brain lesion (≥ 1) as per RANO-BM Criteria, Tretament naive/ Treated- Stable/&#xD;
        Not requiring immediate local therapy known/ Suspected leptomeningeal disease on Stable&#xD;
        corticosteriod dose for 7 days prior screeing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. All 3 parts of Study&#xD;
&#xD;
               -  Major surgery &lt;4 weeks of C1D1&#xD;
&#xD;
               -  Evidence of organ dysfunction or inadequate bone marrow reserve or any clinically&#xD;
                  significant finidngs&#xD;
&#xD;
               -  Patients with visceral crisis or impending visceral crisis and rapidly&#xD;
                  progressing disease&#xD;
&#xD;
               -  Serology tests +ve for HIV, HCV, HBsAg&#xD;
&#xD;
               -  Inability to swallow oral medication&#xD;
&#xD;
               -  H/o any relevant allergy/hypersensitivity/idiosyncrasy to drugs/ chemically&#xD;
                  related to Study drug or its excipients&#xD;
&#xD;
               -  Received an IMP within 30 days/5 half life to C1D1&#xD;
&#xD;
               -  Prior treatment with other oral SERDs&#xD;
&#xD;
               -  Use of concomitant medication that might reasonably influence the results or&#xD;
                  interpretation of the study&#xD;
&#xD;
               -  Requires concurrent systemic anticancer treatment at any time during the study&#xD;
                  treatment period&#xD;
&#xD;
               -  Known or suspected history of significant drug abuse/Alcohol as judged by the&#xD;
                  Investigator&#xD;
&#xD;
               -  Known or suspected history of excessive intake of alcohol in the 12 months prior&#xD;
                  to study entry&#xD;
&#xD;
               -  Malabsorption syndrome/IBD/other illness that would affect oral absorption of&#xD;
                  Study drug&#xD;
&#xD;
               -  Uncontrolled intercurrent illness that would limit compliance with study&#xD;
                  requirements / have impact on endpoints / safety&#xD;
&#xD;
               -  ≤6 months H/o MI/unstable angina, ongoing &gt; G2 cardiac dysrhythmia, prolonged&#xD;
                  QTcF/ uncontrolled AF, coronary/peripheral artery bypass graft, HF of NYHA_Class&#xD;
                  II or greater and CVA (+TIA)&#xD;
&#xD;
               -  H/o Endometrial intraepithelial neoplasia, other malignancy &lt; 5 yrs prior to&#xD;
                  enrollment&#xD;
&#xD;
               -  Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases,&#xD;
                  or leptomeningeal disease as indicated by clinical symptoms (not applicable to&#xD;
                  Part 3d), carcinomatous meningitis, cerebral edema, and/or progressive growth or&#xD;
                  pulmonary lymphangitic metastases.&#xD;
&#xD;
               -  Current abnormal vaginal bleeding or symptomatic endometrial disorders.&#xD;
&#xD;
          2. For Part 2: Use of other ET that block the estrogen receptor: atleast 8 weeks before&#xD;
             enrollment (28 weeks for fulvestrant) For Part 2: Liver-only metastases (are not&#xD;
             evaluable by FES-PET/CT imaging)&#xD;
&#xD;
          3. For Part 3: Any brain lesion requiring immediate local therapy (which includes but is&#xD;
             not limited to WBRT, SRS, or surgical resection, for treatment of brain metastases)&#xD;
             Requires increase in the dose of corticosteroids for control of CNS symptoms due to&#xD;
             brain metastases Poorly controlled (&gt; 2 per month ) generalized or complex partial&#xD;
             seizures Who are taking concurrent enzyme-inducing antiepileptic drugs (EIAED) Who has&#xD;
             evidence of significant (ie, symptomatic) intracranial haemorrhage Contra indications&#xD;
             for repeated MRI assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical Developement</last_name>
    <phone>9122 66455645</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Narayana Multispeciality Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380023</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Rushabh Kothari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HealthCare Global Enterprises Ltd</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Satheesh CT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences (AIMS)</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Pavithran Kheechilat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCG Manavata cancer Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Aditya Adhav</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMMF's Deenanath Mangeshkar Hospital &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Chetan Deshmukh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Noble Hospital Pvt. Ltd.,</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Minish Jain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Krishna Kumar Rathnam</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

